We are live on ! Find out more
FLNA

Filana Therapeutics
FLNA

39 hedge funds and large institutions have $15.3M invested in Filana Therapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $10.9M → $15.3M (+$4.36M)

0.63% less ownership

Funds ownership: 5.93% → 5.3% (-0.63%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

15% less funds holding

Funds holding: 46 → 39 (-7)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $21K

Holders
39
Holders Change
-7
Holders Change %
-15.22%
% of All Funds
0.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
8
Closed
8
Calls
–
Puts
$21K
Net Calls
-$21K
Net Calls Change
-$25K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$985K
2
ARTA
A.R.T. Advisors
New York
+$52K
3
Citadel Advisors
Citadel Advisors
Florida
+$17.3K
4
TSS
Two Sigma Securities
New York
+$17.3K
5
TU
TDAM USA
Ontario, Canada
+$15.3K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$648K
2
AFM
Anson Funds Management
Texas
-$262K
3
Renaissance Technologies
Renaissance Technologies
New York
-$125K
4
ZIM
Zacks Investment Management
Illinois
-$117K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$77.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
First Eagle Investment Management
1
First Eagle Investment Management
New York
$5.9M – – –
NCM
2
Nantahala Capital Management
Connecticut
$2.17M -$648K -142,858 -29%
BI
3
BVF Inc
California
$2.04M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.45M – – –
BlackRock
5
BlackRock
New York
$1.36M +$985K +217,105 New
Renaissance Technologies
6
Renaissance Technologies
New York
$574K -$125K -27,628 -23%
BCM
7
Bridgeway Capital Management
Texas
$380K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$183K +$676 +149 +0.5%
GF
9
Gabelli Funds
New York
$156K – – –
Bank of New York Mellon
10
Bank of New York Mellon
New York
$154K +$10.9K +2,410 +11%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$142K -$77.9K -17,159 -43%
GI
12
GAMCO Investors
Connecticut
$98K – – –
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$89K – – –
Northern Trust
14
Northern Trust
Illinois
$83K -$73 -16 -0.1%
ARTA
15
A.R.T. Advisors
New York
$82K +$52K +11,457 +674%
TSS
16
Two Sigma Securities
New York
$55K +$17.3K +3,804 +76%
GS
17
Gagnon Securities
New York
$42K +$1.11K +245 +4%
TA
18
Teton Advisors
New York
$40K – – –
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$37K -$25K -5,503 -48%
ACM
20
Avalon Capital Management
California
$31K – – –
Goldman Sachs
21
Goldman Sachs
New York
$30K -$11.1K -2,438 -34%
Connor, Clark & Lunn Investment Management (CC&L)
22
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$28K – – –
Bank of America
23
Bank of America
North Carolina
$24K -$100 -22 -0.6%
Citadel Advisors
24
Citadel Advisors
Florida
$24K +$17.3K +3,808 New
State Street
25
State Street
Massachusetts
$22K – – –
1
2

FLNA Hedge Fund Activity: Q1 2017 in Review

39 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2017, worth a combined $15.3M — up 40% from $10.9M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of FLNA and 5 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was BlackRock, opening a new position worth an estimated $985K. The largest seller was Nantahala Capital Management, cutting an estimated $648K.

  • 39 institutional investors held Filana Therapeutics (FLNA) as of Q1 2017, down from 46 in Q4 2016.
  • Funds reported $15.3M of Filana Therapeutics stock for Q1 2017, up 40% quarter-over-quarter.
  • 5 funds opened new Filana Therapeutics positions in Q1 2017 and 8 closed out, a net change of -3 holders.
  • The largest Filana Therapeutics buyer in Q1 2017 was BlackRock, an estimated $985K added.
  • The largest Filana Therapeutics seller in Q1 2017 was Nantahala Capital Management, an estimated $648K sold.

Based on aggregated 13F filings for Q1 2017.